NASDAQ:CYTX - Cytori Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.31 -0.01 (-3.16 %) (As of 04/19/2019 04:00 PM ET)Previous Close$0.3060Today's Range$0.28 - $0.320152-Week Range$0.22 - $3.20Volume274,175 shsAverage Volume665,970 shsMarket Capitalization$5.00 millionP/E RatioN/ADividend YieldN/ABeta2.04 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA. Receive CYTX News and Ratings via Email Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CYTX Previous Symbol CUSIP23283K10 CIK1095981 Webwww.cytori.com Phone858-458-0900Debt Debt-to-Equity RatioN/A Current Ratio0.55 Quick Ratio0.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.67 million Price / Sales1.36 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book0.87Profitability EPS (Most Recent Fiscal Year)($1.71) Net Income$-12,630,000.00 Net Margins-267.93% Return on Equity-241.90% Return on Assets-60.17%Miscellaneous Employees37 Outstanding Shares16,326,000Market Cap$5.00 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions What is Cytori Therapeutics' stock symbol? Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX." When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work? Shares of Cytori Therapeutics reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split. How were Cytori Therapeutics' earnings last quarter? Cytori Therapeutics Inc (NASDAQ:CYTX) released its quarterly earnings data on Monday, April, 1st. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The biotechnology company had revenue of $1.10 million for the quarter. Cytori Therapeutics had a negative return on equity of 241.90% and a negative net margin of 267.93%. View Cytori Therapeutics' Earnings History. When is Cytori Therapeutics' next earnings date? Cytori Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Cytori Therapeutics. What price target have analysts set for CYTX? 2 brokerages have issued 1-year price objectives for Cytori Therapeutics' stock. Their forecasts range from $5.00 to $20.00. On average, they expect Cytori Therapeutics' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 3,985.0% from the stock's current price. View Analyst Price Targets for Cytori Therapeutics. What is the consensus analysts' recommendation for Cytori Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytori Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytori Therapeutics. What are Wall Street analysts saying about Cytori Therapeutics stock? Here are some recent quotes from research analysts about Cytori Therapeutics stock: 1. Maxim Group analysts commented, "Cytori reported 4Q18 with product sales of $0.4M (celution system) and contract revenues of $0.7M, net loss was ($2.2M). The company ended the period with $5.3M in cash, which does not include the asset sale announced concurrently with earnings." (4/1/2019) 2. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (1/15/2019) 3. HC Wainwright analysts commented, "Our valuation for Cytori is based on success with the current therapeutics pipeline with probability of success factors weighted in each therapeutic area. These forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum- of-the-parts (SOP) models." (9/18/2018) Has Cytori Therapeutics been receiving favorable news coverage? News coverage about CYTX stock has been trending positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytori Therapeutics earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the next few days. Are investors shorting Cytori Therapeutics? Cytori Therapeutics saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 76,608 shares, a drop of 87.4% from the March 15th total of 608,907 shares. Based on an average trading volume of 793,444 shares, the short-interest ratio is presently 0.1 days. Approximately 0.6% of the company's stock are short sold. View Cytori Therapeutics' Current Options Chain. Who are some of Cytori Therapeutics' key competitors? Some companies that are related to Cytori Therapeutics include Co-Diagnostics (CODX), Dynatronics (DYNT), Invivo Therapeutics (NVIV), Alliqua Biomedical (ALQA), Biostage (BSTG), Obalon Therapeutics (OBLN), Presbia (LENS), Neurometrix (NURO), United American Healthcare (UAHC), Encision (ECIA), CELLECT BIOTECH/S (APOP), Regenicin (RGIN), Cytocore (MDIT), AdvanSource Biomaterials Corpration (ASNB) and Amedica (AMDA). What other stocks do shareholders of Cytori Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Exelixis (EXEL), Shire (SHPG), Bank of America (BAC), Micron Technology (MU), Inovio Pharmaceuticals (INO), BCE (BCE), Athersys (ATHX), Opko Health (OPK) and Synergy Pharmaceuticals (SGYP). Who are Cytori Therapeutics' key executives? Cytori Therapeutics' management team includes the folowing people: Marc H. Hedrick, President, Chief Executive Officer & DirectorGary S. Titus, Chief Financial OfficerMark T. Marino, Chief Medical Officer & Senior Vice PresidentJohn K. Fraser, Chief ScientistRuss Havranek, VP-Global Marketing & Business Development Who are Cytori Therapeutics' major shareholders? Cytori Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.86%). Company insiders that own Cytori Therapeutics stock include Ag Postfinance and Bank Sa Swissquote. View Institutional Ownership Trends for Cytori Therapeutics. Which major investors are buying Cytori Therapeutics stock? CYTX stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Cytori Therapeutics. How do I buy shares of Cytori Therapeutics? Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cytori Therapeutics' stock price today? One share of CYTX stock can currently be purchased for approximately $0.3060. How big of a company is Cytori Therapeutics? Cytori Therapeutics has a market capitalization of $5.00 million and generates $3.67 million in revenue each year. The biotechnology company earns $-12,630,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe. What is Cytori Therapeutics' official website? The official website for Cytori Therapeutics is http://www.cytori.com. How can I contact Cytori Therapeutics? Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected] MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 374 (Vote Outperform)Underperform Votes: 243 (Vote Underperform)Total Votes: 617MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/20/2019 by MarketBeat.com StaffFeatured Article: Why do company’s buyback their stock?